Organon introduces JADA system for postpartum hemorrhage

By Hwang, Byung-woo | translator Kang, Shin-Kook

24.07.18 05:00:55

가나다라 0

New product approval comes nearly 3 years after the company’s establishment in Korea in June 2021

About 20% of mothers experience postpartum hemorrhage... targets the unmet need

Conventional balloon dilation takes 12 to 24 hours...whereas JADA controls the bleeding in a median of 3 minutes

Organon, which emphasizes its focus on women's health after spinning off from MSD, has launched its first product in Korea.

The JADA system (JADA), a medical device for the control and treatment of postpartum hemorrhage, is the first product the company released in Korea since Organon officially launched its Korean subsidiary in June 2021.

JADA, which can be used for intrauterine negative pressure hemostasis, was recognized as a safe and effective new health technology by the National Evidence-based Healthcare Collaborating Agency (NECA) late last month.

For Organon, the approval of JADA is significant because it is the first new product the company has introduced i

Hwang, Byung-woo(tuai@dailypharm.com)

If you want to see the full article, please JOIN US (click)